Holen Sie sich die Stockscreener-App
6.32
0.96%
0.06
Handel nachbörslich:
6.32
Schlusskurs vom Vortag:
$6.26
Offen:
$6.25
24-Stunden-Volumen:
1.11M
Relative Volume:
0.78
Marktkapitalisierung:
$283.13M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-6.32
EPS:
-1
Netto-Cashflow:
$-100.85M
1W Leistung:
+5.51%
1M Leistung:
+35.62%
6M Leistung:
-53.77%
1J Leistung:
-69.00%
1-Tages-Spanne:
$6.13
$6.585
1-Wochen-Bereich:
$5.83
$6.585
52-Wochen-Spanne:
$4.32
$25.42
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Vergleichen Sie PRTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
6.32 | 283.13M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Prothena announces 63% workforce reduction following birtamimab halt - Investing.com
Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus
Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus
Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks
Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus
Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus
Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus
Prothena to cut workforce by 63% amid strategic review - Investing.com
Prothena announces corporate restructuring - MarketScreener
Prothena Announces Corporate Restructuring - Business Wire
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Insider Monkey
(PRTA) Trading Signals - news.stocktradersdaily.com
Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX
Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha
Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks
Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com
Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus
Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa
Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com
Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World
Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World
Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
(PRTA) Technical Data - news.stocktradersdaily.com
Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prothena Corporation Plc-Aktie (PRTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):